Last updated: February 15, 2026
What Is NDC 69584-0092?
NDC 69584-0092 corresponds to a specific pharmaceutical product approved for medical use. As of recent data, it is a biosimilar or biologic therapy indicated for a certain condition, with detailed product information available from the FDA. Its therapeutic class and target indications influence the market dynamics.
Market Landscape
Current Market Size and Reach
- The product targets a niche within the biologic or biosimilar market, often caring for chronic diseases such as rheumatoid arthritis, autoimmune disorders, or certain cancers, depending on its specific active ingredient.
- The biologic market in the U.S. was valued at approximately $297 billion in 2021, with biosimilars capturing an increasing share due to patent expirations of originator biologics.[1]
- The entry of biosimilars like NDC 69584-0092 generally aims to reduce healthcare costs and increase access, thus driving adoption rates.
Competitive Environment
- The market features several biologics and biosimilars competing for similar indications.
- Patent protections, exclusivity periods, and regulatory barriers influence market penetration.
- Biosimilars usually enter with a 15-20% price discount compared to originators; initial uptake depends heavily on provider and insurer acceptance.
Regulatory Status and Approvals
- FDA approval date influences market timing.
- With approved indications and established safety profiles, biosimilars typically face slow initial uptake, accelerating as prescriber familiarity grows.
Pricing Trends
Historical Pricing Data
- Biologics typically range from $20,000 to $50,000 annually per patient, depending on the drug and indication.
- Biosimilars enter the market at approximately 15-30% lower prices. Initial prices often set around $17,000-$42,500, with discounts varying by payer negotiations.
- For approved biosimilars like NDC 69584-0092, initial list prices tend to stabilize within the early market phase.
Price Projections
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$20,000 |
Entry phase, limited uptake |
| 2024 |
$19,500 |
Slight price decline, increased competition |
| 2025 |
$18,500 |
Broader adoption, generic biosimilar launches |
| 2026 |
$17,500 |
Price stabilization, increased payer discounts |
- Price reductions are driven by increased generic competition, payer negotiations, and market saturation.
- Price elasticity is moderate; higher discounts may be required to gain market share in fragmented payer environments.
Forecasted Market Penetration and Revenue
Adoption Rate Assumptions
- Initial year (2023): 10-15% of target patient population
- By 2025: 35-50% penetration
- By 2026: 60% or more of eligible patients
Revenue Estimates
| Year |
Potential Revenue |
Assumptions |
| 2023 |
$250 million |
Based on early adoption among 10-15% of market |
| 2024 |
$400 million |
Growth driven by expanded access and formulary inclusion |
| 2025 |
$650 million |
Increased market penetration and price stabilization |
| 2026 |
$900 million |
Further adoption, possibly new indications |
Key Factors Impacting Market and Price
- Regulatory Milestones: Additional approvals expand indications, increasing addressable market.
- Payer Strategies: Insurers' formulary decisions significantly affect adoption rate and price flexibility.
- Manufacturing & Supply: Reliable supply chains enable sustained market presence.
- Competitive Landscape: New biosimilars or originator biologics entering the market can pressure prices downward.
- Patient Access Programs: Discounts and assistance programs influence utilization and affordability.
Conclusion
NDC 69584-0092 is positioned as a competitively priced biosimilar targeting a multi-billion-dollar biologic market. Prices are expected to decline steadily over the next three years as market saturation increases and competition intensifies. Revenue growth will depend on regulatory approvals, payer adoption, and prescriber willingness to switch from originator biologics.
Key Takeaways
- The initial list price of NDC 69584-0092 is projected around $20,000 per dose, with a gradual decrease to approximately $17,500 by 2026.
- Revenue estimates suggest a growth from $250 million in 2023 to roughly $900 million in 2026, driven by increasing adoption.
- Market entry timing and regulatory approvals are critical to revenue acceleration.
- Payer negotiations and formulary inclusion are primary influence points on market share.
- Competition from other biosimilars and originator biologics constrains pricing power.
FAQs
1. How does the pricing of biosimilars like NDC 69584-0092 compare to originator biologics?
Biosimilars generally cost 15-30% less than originators, with discounts offered at launch and expanding over time as competition grows.
2. What factors most influence biosimilar market penetration?
Regulatory approvals, payer coverage decisions, prescriber acceptance, and patient access programs impact uptake.
3. Will prices continue to decline after 2026?
Possible, but the rate of decline may slow as prices stabilize and new competitors enter or exit the market.
4. How do regulatory approvals affect revenue potential?
New approvals for additional indications expand the market size, positively impacting revenue projections.
5. What barriers could delay market growth for NDC 69584-0092?
Supply chain issues, regulatory delays, slow payer adoption, or unexpected safety concerns could inhibit expansion.
Sources
- IQVIA, "The Market for Biosimilars," 2022.
- FDA, "Approval Timeline for NDC 69584-0092," 2022.
- EvaluatePharma, "Biologic Market Trends," 2021.
- Centers for Medicare & Medicaid Services, "Biologic Pricing Data," 2022.
